Reports an amplification-free FRET-based assay that uses an RNaseH1-linked acceptor and DNA-spiked fluorescent nanocage to detect serum microRNAs for cancer diagnosis and single-base mismatch discrimination.
Key Takeaways
- Please note there may be errors present which affect the content, and all legal disclaimers apply
- Cancer-associated microRNAs are promising biomarkers for early cancer diagnosis
- Current microRNA detections – which are based on polymerase chain reaction